NO20055538L - Analysis and use of PARI polymorphisms for risk assessment of cardiovascular diseases - Google Patents

Analysis and use of PARI polymorphisms for risk assessment of cardiovascular diseases

Info

Publication number
NO20055538L
NO20055538L NO20055538A NO20055538A NO20055538L NO 20055538 L NO20055538 L NO 20055538L NO 20055538 A NO20055538 A NO 20055538A NO 20055538 A NO20055538 A NO 20055538A NO 20055538 L NO20055538 L NO 20055538L
Authority
NO
Norway
Prior art keywords
cardiovascular diseases
pari
polymorphisms
analysis
risk assessment
Prior art date
Application number
NO20055538A
Other languages
Norwegian (no)
Inventor
Sylvain Ricard
Detlef Kozian
Karl-Ernst Siegler
Jean-Francois Deleuze
Sandrine Mace
Joerg Czech
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20055538L publication Critical patent/NO20055538L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

The invention relates to polynucleotide sequences comprising genetic variations of PAR 1 gene on positions 3090 and/or 3329. Surprisingly, the presence of said variants in humans correlates with specific cardiovascular diseases. The invention also relates to methods for the detection of said genetic variations.
NO20055538A 2003-04-24 2005-11-23 Analysis and use of PARI polymorphisms for risk assessment of cardiovascular diseases NO20055538L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10318496A DE10318496A1 (en) 2003-04-24 2003-04-24 Analysis and use of PAR 1 polymorphisms for risk assessment for cardiovascular diseases
PCT/EP2004/004035 WO2004094470A1 (en) 2003-04-24 2004-04-16 Analysis and use of par 1 polymorphisms for the risk estimation of cardiovascular diseases

Publications (1)

Publication Number Publication Date
NO20055538L true NO20055538L (en) 2005-11-23

Family

ID=33304897

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055538A NO20055538L (en) 2003-04-24 2005-11-23 Analysis and use of PARI polymorphisms for risk assessment of cardiovascular diseases

Country Status (16)

Country Link
EP (1) EP1622940B1 (en)
JP (1) JP4728949B2 (en)
KR (1) KR20060006939A (en)
CN (1) CN1791613A (en)
AT (1) ATE407145T1 (en)
AU (1) AU2004232459B2 (en)
BR (1) BRPI0409688A (en)
CA (1) CA2522815A1 (en)
DE (2) DE10318496A1 (en)
DK (1) DK1622940T3 (en)
ES (1) ES2312990T3 (en)
IL (1) IL171477A (en)
MX (1) MXPA05011464A (en)
NO (1) NO20055538L (en)
RU (1) RU2380422C2 (en)
WO (1) WO2004094470A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2453606C2 (en) * 2010-07-16 2012-06-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" Method for extended screening of predisposition to cardiovascular diseases and biochip for implementing such method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330790A1 (en) * 1998-05-04 1999-11-11 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Method and device for isolating nucleic acids
DE19819889A1 (en) * 1998-05-04 1999-11-11 Fraunhofer Ges Forschung Isolating nucleic acid from samples by binding to array of immobilized, random capture probes
US6322980B1 (en) * 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence

Also Published As

Publication number Publication date
AU2004232459A1 (en) 2004-11-04
KR20060006939A (en) 2006-01-20
CA2522815A1 (en) 2004-11-04
WO2004094470A1 (en) 2004-11-04
EP1622940A1 (en) 2006-02-08
DE10318496A1 (en) 2004-11-25
ATE407145T1 (en) 2008-09-15
RU2005136430A (en) 2006-04-20
IL171477A (en) 2010-11-30
BRPI0409688A (en) 2006-04-18
JP2007534293A (en) 2007-11-29
DE502004007990D1 (en) 2008-10-16
CN1791613A (en) 2006-06-21
RU2380422C2 (en) 2010-01-27
EP1622940B1 (en) 2008-09-03
ES2312990T3 (en) 2009-03-01
DK1622940T3 (en) 2009-01-12
JP4728949B2 (en) 2011-07-20
MXPA05011464A (en) 2006-03-08
AU2004232459B2 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
WO2009117122A8 (en) Genetic analysis
WO2007067968A3 (en) Effects of inhibitors of fgfr3 on gene transcription
ATE410524T1 (en) METHOD AND NUCLEIC ACIDS FOR THE ANALYSIS OF CELLULAR PROLIFERATION DISORDERS
EP1583770A4 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
DE602005009702D1 (en) ESR1 AND NUTRITIONAL CANCER
ATE540129T1 (en) TARGET FOR THE THERAPY OF COGNITIVE DISABILITIES
SI1730315T1 (en) Polymorphisms in nod2/card15 gene
DK1515752T3 (en) ACE2 activation for the treatment of heart, lung and kidney diseases and hypertension
ATE454468T1 (en) DETECTION OF THE INSTABILITY OF MICROSATELLITES AND USE THEREOF IN TUMOR DIAGNOSIS
EP1948831A4 (en) Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
DK1692102T3 (en) Compositions and Methods for Detecting and Treating Diseases and Conditions Associated with Chemokine Receptors
DE60326748D1 (en) METHOD FOR IDENTIFYING BREAST CANCER RISK
WO2004026107A3 (en) Kits and methods for assessing skin health
ATE513929T1 (en) GENES AFFECTING HUMAN MEMORY PERFORMANCE
WO2005047536A3 (en) Detection of genomic amplification and deletion in cancer
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
DK1689886T3 (en) Molecular marker associated with CMV resistance and its use
NO20055538L (en) Analysis and use of PARI polymorphisms for risk assessment of cardiovascular diseases
FR2883298B1 (en) NUCLEIC ACID FRAGMENTS AND METHOD OF SPECIFIC DETECTION BY MOLECULAR IDENTIFICATION OF DIFFERENT SPECIES OF BACTERIA OF THE GENUS ACINETOBACTER
ATE494390T1 (en) METHOD AND NUCLEIC ACIDS FOR ANALYZING DISORDERS IN COLON CELL PROLIFERATION
MX2009008788A (en) Serpine1 polymorphisms are predictive of response to activated protein c administration and risk of death.
WO2004005886A3 (en) Kits and methods for assessing cardiovascular health
WO2006097462A3 (en) Compositions and methods for treating inflammatory cns disorders
WO2002080755A3 (en) Kits and methods for assessing oxidative stress
EP1992701A3 (en) Kits and methods for assessing oxidative stress